Changes in gastric acid secretion assayed by endoscopic gastrin test before and after *Helicobacter pylori* eradication

K Iijima, S Ohara, H Sekine, T Koike, K Kato, S Asaki, T Shimosegawa, T Toyota

**Abstract**

*Background*—It remains controversial whether or not *Helicobacter pylori* infection causes altered gastric acid secretion. A novel test for evaluating gastric acid secretion (endoscopic gastrin test; EGT) has recently been developed.  

*Aim*—To investigate by EGT the effects of *H pylori* eradication on the state of gastric acid secretion in patients with peptic ulcer.  

*Methods*—Twenty-six patients with duodenal ulcer and 33 with gastric ulcer, for all of whom *H pylori* infection had been documented, were studied by EGT, histological examination of gastric mucosa, and measurement of plasma gastrin levels before and one and seven months after *H pylori* eradication.  

*Results*—In patients with duodenal ulcer, the mean EGT value before *H pylori* eradication was higher than that in *H pylori* negative controls, but it had decreased significantly seven months after the treatment. In contrast, the mean EGT value of patients with gastric ulcer before *H pylori* eradication was lower than that in *H pylori* negative controls, but it had increased one month after the treatment; this was followed by a slight decrease at seven months. In both groups, mean EGT values seven months after the treatment were not significantly different from the mean control value.  

*Conclusions*—The reduced acid secretion in gastric ulcer patients and gastric acid hypersecretion in duodenal ulcer patients were both normalised after the clearance of *H pylori*.

**Subjects and methods**

*SUBJECTS*  
Twenty-nine patients with DU and 35 patients with GU in whom *H pylori* infection had been confirmed were enrolled. Active ulcer disease had been confirmed endoscopically within the six months preceding entry into the study. Patients with both GU and DU were excluded. GUs were located on the lesser curvature of the incisura angularis in 24 patients, in the corpus in 10 patients, and in the antrum in one. *H pylori* infection status was determined by the rapid urease test and histology. None of the patients had taken non-steroidal anti-inflammatory drugs, antibiotics, or proton pump inhibitors within 15 days of study entry. All patients were asked to stop taking H₂ blockers at least 48 hours before study entry.  

At entry, each patient had upper gastrointestinal endoscopy, which included EGT and biopsies from the antrum and body of the stomach for histological examination and rapid urease test, as well as determination of fasting plasma gastrin concentrations. After this initial assessment, patients received eradication treatment consisting of omeprazole 20 mg a day, metronidazole 500 mg twice a day, and clarithromycin 200 mg twice a day for a week, and *H pylori* status was redetermined by a combination of histological examination, rapid urease test, and 13C-urea breath test one month later. All patients in whom eradication was confirmed at this point had a repeat determination of *H pylori* infection status seven months later. Upper gastrointestinal endoscopy...
including EGT, histological examination, and plasma gastrin measurement, was repeated one and seven months after the eradication treatment. Asymptomatic subjects matched for age, sex, and body weight were selected as controls for H pylori positive patients with DU or GU, from the subjects who underwent endoscopy during the study period and were confirmed to be H pylori negative by rapid urease test and histological examination. The study was conducted in accordance with the Helsinki Declaration as revised in Tokyo, and informed consent was obtained from each subject.

ENDOSCOPIC GASTRIN TEST
The technique for performing EGT has been reported previously.12 Briefly, after an overnight fast, subjects were injected intramuscularly with tetragastrin (Gastopsin Nippon Kayaku, Tokyo, Japan), 4 µg/kg, before endoscopy. Endoscopy was begun about 15 minutes after the tetragastrin injection. After the endoscope had entered the stomach, pooled gastric fluid was aspirated and discarded. Gastric fluid secreted between 20 and 30 minutes after the tetragastrin injection was aspirated and collected under direct visualisation during routine endoscopic examination of the stomach and duodenal bulb. Biopsy specimens were then taken when indicated, and the endoscope was removed. The volume of sample collected over the 10 minute period was recorded, and its H+ concentration was determined by titration. The acid output in the 10 minute period was calculated by multiplying the volume by the H+ concentration, and the EGT value was expressed as mEq/10 min. We have shown previously that EGT values correlate very closely with peak acid output determined by conventional methods (correlation coefficient = 0.92) and have high reproducibility (coefficient of variation = 5.6%).12

HISTOLOGICAL EXAMINATION
Biopsy specimens taken endoscopically from the gastric antrum and upper body in the greater curvature were evaluated histologically. Using the Updated Sydney system, the degree of inflammation, activity, and atrophy were scored from 0 to 3.13 The inflammation and activity scores were added together to form a gastritis score.

13C-UREA BREATH TEST
The 13C-urea breath test was performed as previously reported.14 Briefly, after a baseline breath sample had been taken, fasting patients were given 100 mg [13C]urea in 100 ml water. An additional breath sample was taken 20 minutes after urea administration. Breath samples obtained at baseline and after drug administration were analysed for 13CO2 with a mass spectrometer. We determined the cut off value for a positive urea breath test at 2.5‰.

GASTRIN DETERMINATION
A fasting blood sample was obtained for gastrin determination, and the plasma stored at −20°C. Plasma gastrin concentrations were measured with a radioimmunoassay (Dainabot Co, Tokyo, Japan).

<p>| Table 1: Comparison of demographics of patients with Helicobacter pylori infection who also have either duodenal ulcer (DU) or gastric ulcer (GU) |</p>
<table>
<thead>
<tr>
<th>DU</th>
<th>GU</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>26</td>
<td>33</td>
</tr>
<tr>
<td>Men/women (n)</td>
<td>18/8</td>
<td>28/5</td>
</tr>
<tr>
<td>Age (years)</td>
<td>35 (11)</td>
<td>55 (12)</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>63 (16)</td>
<td>62 (10)</td>
</tr>
<tr>
<td>Serum gastrin (pg/ml)</td>
<td>104 (44)</td>
<td>110 (73)</td>
</tr>
<tr>
<td>EGT value (mEq/10 min)</td>
<td>5.1 (2.7)</td>
<td>2.9 (1.8)</td>
</tr>
</tbody>
</table>

Data represent mean (SD). EGT, endoscopic gastrin test.

STATISTICAL METHODS
The EGT values and gastrin concentrations are expressed as means (SD), and Student’s unpaired t test (for unpaired values), and Student’s paired t test (for paired values) were used to compare group means. Histological scores were expressed as mean (SD), and the statistical significance of differences in histological scores was determined by the Mann-Whitney test (for unpaired values) and the Wilcoxon rank sum test (for paired values). p<0.05 was considered to be statistically significant.

Results

PATIENT PROFILES
H pylori eradication was achieved in 26 of 29 patients with DU, and in 33 of 35 patients with GU. All patients in whom H pylori organisms were cleared at one month after eradication treatment remained free of H pylori infection at seven months after the treatment. No patient experienced a relapse during this period. Three patients with DU (two men) and two with GU (both men) in whom H pylori organisms were not cleared were excluded from further study. Table 1 shows details of the remaining subjects. The mean age was higher in the group with GU than in the group with DU, whereas the mean body weight was identical in the two groups.

HISTOLOGICAL EXAMINATION

Gastritis score
Before eradication, there was no significant difference between the patients with DU and those with GU with regard to the degree of gastritis in the antrum (DU mean, 3.9 (1.0); GU mean, 3.5 (1.0); fig 1A). In contrast, the mean gastritis score in the gastric body of patients with GU was 2.1 (1.1), which is significantly higher than the mean score of 1.3 (0.7) in patients with DU (p=0.01) (fig 1B). At one month after the eradication, the mean gastritis score in the antrum had decreased significantly to 1.3 (0.6) in the DU group (p<0.01) and 1.4 (0.5) in the GU group (p<0.01); at seven months after eradication, it showed a slight further decrease in both groups (1.1 (0.4) in patients with DU, 0.9 (0.5) in patients with GU). The difference in the mean gastritis score between one and seven months after the eradication was significant only in the GU group (p<0.01). The change in gastritis score in the body after eradication was similar to that in the antrum. The mean gastritis score in the body fell significantly from 2.1 (1.1), the value before eradication, to 0.4 (0.5) in patients with DU and from 1.3 (0.6) to 0.7 (0.5) in patients with GU at one month (both p<0.01). It fell further to 0.2 (0.4)
in patients with DU and to 0.4 (0.5) in patients with GU at seven months, but the decreases between one and seven months were not significant in either group (fig 2).

**Atrophy score**

Mucosal atrophy was more prevalent in patients with GU than in those with DU in both the antrum and body, whereas antral atrophy was more marked than body atrophy in both patient groups. Before eradication, the mean atrophy score in the antrum of patients with GU was 1.7 (0.8), and was significantly higher than the mean score of 0.8 (0.7) in patients with DU (p<0.01) (fig 3A). Similarly, in the body, the mean atrophy score was significantly higher in patients with GU than in those with DU (0.3 (0.6) and 0.04 (0.2) respectively; p<0.05; fig 3B). During follow up after eradication, there was no statistically significant change in the degree of antral or body atrophy in patients with either DU or GU, although there was a trend toward improvement in those with GU (antrum, 1.5 (0.8) at one month, 1.3 (1.0) at seven months, p = 0.1; body, 0.2 (0.3) at one month, 0.1 (0.2) at seven months, p = 0.07) (fig 4).

**FASTING PLASMA GASTRIN**

Before eradication, fasting plasma gastrin concentrations were similar in H pylori positive patients with DU and those with GU (DU, 104 (44) pg/ml; GU, 110 (73) pg/ml) (table 2), and the concentrations in both groups were...
significantly higher than those in *H pylori* negative controls (controls for patients with DU, 62 (16) pg/ml, \( p < 0.01 \); controls for patients with GU, 63 (22) pg/ml, \( p < 0.01 \)). At one month after eradication, the mean gastrin concentrations decreased significantly to 60 (14) pg/ml in patients with DU and to 69 (31) pg/ml in those with GU. Neither of these values were significantly different from those in *H pylori* negative controls. After seven months, there was no significant fall in gastrin concentration in either patient group compared with the one month value (table 2).

**ENDOSCOPIC GASTRIN TEST**

Before eradication, the mean EGT value was significantly higher in patients with DU than in those with GU (5.1 (2.7) \( v \) 2.9 (1.8) mEq/10 min, \( p < 0.01 \)) (table 2). In patients with DU with *H pylori* infection, the mean EGT value was significantly higher than in *H pylori* negative controls (5.1 (2.7) \( v \) 3.7 (1.4) mEq/10 min, \( p < 0.01 \)). One month after eradication, no significant change was seen in EGT values in the patients with DU (5.2 (2.5) mEq/10 min), whereas it had fallen significantly at seven months after the eradication (from 5.1 (2.7) mEq/10 min before eradication to 3.9 (1.9) mEq/10 min, \( p < 0.01 \)). The value at seven months was not significantly different from that in *H pylori* negative controls (fig 5, table 2).

In patients with GU with *H pylori* infection, the mean EGT value was significantly lower than in *H pylori* negative controls (2.9 (1.8) \( v \) 4.1 (1.6) mEq/10 min, \( p < 0.01 \)). The mean EGT value of patients with GU with *H pylori* infection and gastric acid secretion

---

**Figure 3** Atrophy scores of the antrum (A) and body (B). Before eradication of *H pylori*, the mean atrophy score of the antrum in patients with gastric ulcer (GU) was significantly higher than that of patients with duodenal ulcer (DU). Similarly, the mean atrophy score of the gastric body was significantly higher in the patients with GU than patients with DU. \( *p < 0.05 \), \( **p < 0.01 \).

**Figure 4** Changes in atrophy score in the antrum (A) and body (B) caused by *H pylori* eradication. After the eradication, the degree of antral or body atrophy did not change significantly in patients with either duodenal ulcer (DU) or gastric ulcer (GU). Vertical bars represent SD of the mean atrophy score.
infection increased significantly from 2.9 (1.8) mEq/10 min before eradication to 4.9 (2.3) mEq/10 min at one month (p<0.01), and then decreased slightly but significantly to 4.3 (1.9) mEq/10 min at seven months (p<0.05, compared with the one month value). The mean EGT value at seven months was not significantly different from that in H pylori negative controls, but was still higher than that recorded before eradication (4.3 (1.9) vs 2.9 (1.8) mEq/10 min, p<0.01) (fig 6, table 2).

**Discussion**

In this study, we have shown by EGT that H pylori eradication was accompanied by a decrease in acid secretion in patients with DU, while it actually increased after eradication in patients with GU. Before H pylori eradication, patients with DU had greater acid secretion than H pylori negative normal subjects. This finding is in agreement with a previous report. 15 On the other hand, in patients with H pylori positive GU, the mean EGT value was significantly lower than that in H pylori negative normal subjects. This finding is in agreement with a previous report. 15

One month after eradication, the mean EGT value of patients with DU was unchanged compared with before eradication. Previous studies have shown that basal acid output decreases rapidly after H pylori eradication, apparently in direct association with decreased serum gastrin. 6 9 However, the gastrin stimulated acid output shown by EGT, which reflects the total functional parietal cell mass, was unchanged one month after eradication in our study. 4 6 The disparity may be caused by the difference in intervals required to achieve a decrease in the basal and gastrin stimulated acid outputs, as discussed below.

On the other hand, in patients with GU, the mean EGT value had increased rapidly one month after eradication. Recent studies have reported that, although gastric acid secretion was low in H pylori positive patients with gastritis of the corpus, clearance of H pylori organisms rapidly improved the decreased acid secretion. 17 18 Because body gastritis was more pronounced in patients with GU than in those with DU, in agreement with the findings of others, 20 21 the acid secretion, which was subnormal before eradication, increased when the gastric inflammation subsided after eradication in patients with GU. The mechanism by which body gastritis inhibits gastric acid secretion is not clear, but inflammatory cytokines such as interleukin-1 or proteins produced by H pylori may be responsible for reversible inhibition of acid secretion. 22 24

**Table 2 Changes in endoscopic gastrin test (EGT) values and serum gastrin before and after Helicobacter pylori eradication**

<table>
<thead>
<tr>
<th></th>
<th>DU</th>
<th>GU</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before</td>
<td>1 month</td>
</tr>
<tr>
<td>Gastrin (pg/ml)</td>
<td>104 (44)</td>
<td>60 (14)**</td>
</tr>
<tr>
<td>EGT (mEq/10 min)</td>
<td>5.1 (2.7)</td>
<td>5.2 (2.5)</td>
</tr>
</tbody>
</table>

Data are expressed as mean (SD). DU, duodenal ulcer; GU, gastric ulcer.

**p<0.01,** compared with the value before eradication; †p<0.05, ††p<0.01 compared with the value at one month.
Between one and seven months after *H pylori* eradication, significant decreases in acid secretion were seen in both patients with DU and those with GU. The mechanism of this decreased acid secretion may be related in part to a fall in plasma gastrin, which was commonly observed in association with both diseases. That is, gastrin, which exerts trophic effects not only on parietal cells but also on enterochromaffin-like cells, was suppressed for a long time after the eradication, leading to decreased acid secretion because of their reduced cell mass. The half-life of parietal cells in mice is reported to be 23 days and may be even longer in humans. According to a previous study on a patient with curatively resected gastrinoma, maximal acid output decreased by 80% one year after eradication, but the gastrin stimulated acid output had not changed significantly. However, the rate of the decrease in gastrin stimulated acid output after *H pylori* eradication, reported to be 16% by Parente et al, 33% by Harris et al, and 23% in our study, was small compared with the changes in gastrin releasing peptide stimulated output. Therefore a larger population would be needed to detect the slight difference in gastrin stimulated acid output before and after *H pylori* eradication in patients with DU. Gisbert and colleagues also did not find significant differences in gastrin stimulated acid output before and after *H pylori* eradication. In fact, maximal gastrin stimulated acid output before eradication was somewhat lower in their study than in other reports. The most likely reason for the difference was that more than half of the patients with DU had body gastritis, which has been shown to inhibit acid secretion reversibly in oxyntic mucosa, whereas in general, most patients with DU are considered to have antrum predominant gastritis.

There have been few reports on changes in acid secretion before and after *H pylori* eradication in patients with GU. This is the first study showing that stimulated acid output increases after *H pylori* eradication in patients with GU, which supports the report of Furuta and colleagues that gastric juice pH in patients with GU decreases after eradication. However, it is possible that the rate of this increase in acid secretion varies from subject to subject, because acid secretion in patients with GU varies greatly depending on the anatomical location of the ulcers. In particular, in patients with ulcers in the antrum, which are associated with hypersecretion, acid secretion may decrease after *H pylori* eradication as in patients with DU. In the *H pylori* positive patients with GU in this study, elevated plasma gastrin may have increased acid secretion through a direct effect or through a trophic effect on parietal cells and/or enterochromaffin-like cells. However, this effect may be neutralised by coexisting gastritis of the body, which impaired the acid secretory response to increased gastrin. The net effect was to leave these patients with low acid secretion. In patients with GU, acid secretion showed a biphasic response to eradication of *H pylori*. Initially there was a rapid increase in acid secretion concomitant with resolution of body gastritis while the trophic effect was superimposed on an acute decrease in acid secretion. Subsequently a late decrease in acid secretion occurred when the trophic effect on oxyntic mucosa was removed.
It has been shown that eradication of *H pylori* appreciably decreases DU relapse rates,\(^1^\) and our findings support the concept that this may be related, in part, to decreased acid secretion. However, eradication of *H pylori* also decreases GU relapse rates,\(^2^\) in spite of the accompanying increase in acid secretion. The great success of specific antisecretory agents such as H₂ receptor antagonists in the treatment of peptic ulcers has been considered to be evidence that gastric acidity plays a central role in the pathogenesis of peptic ulcer. However, the role of antisecretory drugs in preventing GU relapse seems not to be as important as in DU.\(^3^–^6\) Although some studies\(^7^–^10\) have shown that such drugs exert a considerable effect, other studies\(^11^–^14\) have concluded that they have little or no influence on GU recurrence. The latter findings suggest that, in patients with GU, mucosal defence factors are more important for ulcer recurrence than detrimental factors such as acid secretion, compared with patients with DU.

Considering the preceding studies and our results together, *H pylori* eradication may decrease the rate of relapse in GU by enhancing defence factors, possibly by permitting the resolution of mucosal inflammation. This improved mucosal defence may outweigh the effect of increased acid secretion.

In conclusion, gastrin stimulated maximal acid secretion is abnormal in patients with *H pylori* infection who have peptic ulcer diseases. Patients with DU display hypersecretion and patients with GU display hyposecretion compared with *H pylori* negative normal controls. This secretory disturbance is resolved fully after eradication of *H pylori*. These differing effects of *H pylori* on acid secretion may be related to the distribution of gastritis within the stomach.


\(^7\) Johnson LR. The trophic action of gastrointestinal hormones. *Gastroenterology* 1976;70:278–82.


